Can Astaxanthin Help Manage Asthma in POlluted Areas?

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorMiddlesex University

About this trial

This study will test whether astaxanthin, a naturally occurring antioxidant supplement, can improve lung function, reduce airway inflammation, and improve asthma control in adults with mild-to-moderate asthma. Participants will receive astaxanthin and placebo in random order in a double-blind crossover design. Each treatment period lasts 4 weeks and is separated by a 3-week washout period. The study also measures indoor and personal air pollution exposure to examine whether pollution influences asthma symptoms, airway responsiveness, and response to treatment. Exploratory thoracic bioelectrical impedance spectroscopy will be assessed alongside standard respiratory tests.

Eligibility criteria

Qualifiers

Adults 18+ y

A physician diagnosed asthma condition consistent with BTS/NICE/SIGN (2024)

Asthma managed at GINA (2024) step 1-3 therapy level, with stable maintenance treatment for ≥4 weeks prior to enrolment

No asthma exacerbation requiring systemic corticosteroids within the preceding 6-8 weeks

Disqualifiers

Current smokers or vapers which is associated with chronic airway remodelling, reduce hyperresponsiveness to bronchodilators, and increased neutrophilic inflammation, which can obscure the true effects of asthma-target interventions

Respiratory tract infection within the preceding 4 weeks

Pregnant or lactating individuals

Presence of significant co-morbidities, including CVD or autoimmune or systemic inflammatory diseases

Trial design

Treatments tested in this trial

  • Astaxanthin Oral Capsule
  • Matched Placebo (Capsules)

Treatment groups

25 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Middlesex University

Lead sponsor

AstaReal

Collaborator

BodyStat Ltd.

Collaborator

British Pest Control Association

Collaborator